Anti-PD-L1 Antibody IBC‑Ab002 Shows Safety in Early Alzheimer’s Phase 1b Trial

A Phase 1b clinical trial of IBC‑Ab002, a humanized anti‑PD‑L1 monoclonal antibody, demonstrated a favorable safety and tolerability profile in patients with early‑stage Alzheimer’s disease. The drug, engineered from checkpoint inhibitors used in cancer therapy, temporarily reactivates the peripheral immune system to reduce brain inflammation and clear senescent cells. No treatment‑related serious adverse events or amyloid‑related brain swelling were observed.

The multi‑center study involved 11 sites—five in the United Kingdom, five in Israel, and one in the Netherlands—and was led by Prof. Michal Schwartz at the Weizmann Institute of Science. Biomarker analyses showed reductions in indicators of neuronal injury and synaptic loss, suggesting a potential disease‑modifying effect, though the sample size was too small for statistical confirmation. The trial marks the first human safety test of this novel immunotherapy approach for Alzheimer’s.